OBJECTIVE AND DESIGN: The clearance receptor for natriuretic peptides (NPRC), a candidate gene for essential hypertension, is highly expressed in adipose tissue, where is nutritionally regulated. The objectives of the present study were to sequence the human 5'-flanking regulatory region of NPRC, to identify allelic variants and their frequencies, and to study the genotype/phenotype correlation in hypertensive patients. METHODS AND RESULTS: Using polymerase chain reaction (PCR) and direct automated sequencing, a biallelic (A/C) polymorphism was detected at position -55 in a conserved promoter element named P1. The novel C(-55) variant makes the promoter sequence identical to the mouse gene and introduces a second Hgal site in the amplified DNA, allowing the genotyping of a large number of subjects. In a random sample of 232 white Caucasians the C(-55) allele was more commonly found (81.7% of all alleles) with 155 CC (66.8%), 69 AC (29.7%) and only eight AA (3.5%) genotypes. Atrial natriuretic peptide (ANP) levels were determined in 84 patients with essential hypertension. In the presence of obesity (body mass index (BMI) > or = 30 kg/m2) the homozygous CC hypertensives (n = 21) had significantly lower plasma ANP (33.6 +/- 11.1 pg/ml) compared with the AC patients (n = 11; 46.8 +/- 15.9 pg/ml; P = 0.01), whereas systolic blood pressure (SBP) and mean blood pressure (MBP) had the opposite association (SBP 163.9 +/- 18.7 versus 150.9 +/- 12.9 and MBP 123.3 +/- 12 versus 114.5 +/- 5.9 mmHg; P< 0.05). The difference in ANP levels were also present when overweight patients (BMI > or = 27 kg/m2) were considered. CONCLUSION: A common 'ancestral' C(-55) variant of the NPRC P1 promoter is associated with lower ANP levels and higher SBP and MBP in obese hypertensives. The C(-55) variant, in the presence of increased adiposity, might reduce plasma ANP through increased NPRC-mediated ANP clearance, contributing to higher blood pressure.
OBJECTIVE AND DESIGN: The clearance receptor for natriuretic peptides (NPRC), a candidate gene for essential hypertension, is highly expressed in adipose tissue, where is nutritionally regulated. The objectives of the present study were to sequence the human 5'-flanking regulatory region of NPRC, to identify allelic variants and their frequencies, and to study the genotype/phenotype correlation in hypertensivepatients. METHODS AND RESULTS: Using polymerase chain reaction (PCR) and direct automated sequencing, a biallelic (A/C) polymorphism was detected at position -55 in a conserved promoter element named P1. The novel C(-55) variant makes the promoter sequence identical to the mouse gene and introduces a second Hgal site in the amplified DNA, allowing the genotyping of a large number of subjects. In a random sample of 232 white Caucasians the C(-55) allele was more commonly found (81.7% of all alleles) with 155 CC (66.8%), 69 AC (29.7%) and only eight AA (3.5%) genotypes. Atrial natriuretic peptide (ANP) levels were determined in 84 patients with essential hypertension. In the presence of obesity (body mass index (BMI) > or = 30 kg/m2) the homozygous CC hypertensives (n = 21) had significantly lower plasma ANP (33.6 +/- 11.1 pg/ml) compared with the AC patients (n = 11; 46.8 +/- 15.9 pg/ml; P = 0.01), whereas systolic blood pressure (SBP) and mean blood pressure (MBP) had the opposite association (SBP 163.9 +/- 18.7 versus 150.9 +/- 12.9 and MBP 123.3 +/- 12 versus 114.5 +/- 5.9 mmHg; P< 0.05). The difference in ANP levels were also present when overweight patients (BMI > or = 27 kg/m2) were considered. CONCLUSION: A common 'ancestral' C(-55) variant of the NPRC P1 promoter is associated with lower ANP levels and higher SBP and MBP in obese hypertensives. The C(-55) variant, in the presence of increased adiposity, might reduce plasma ANP through increased NPRC-mediated ANP clearance, contributing to higher blood pressure.
Authors: Xiaofeng Zhu; J H Young; Ervin Fox; Brendan J Keating; Nora Franceschini; Sunjung Kang; Bamidele Tayo; Adebowale Adeyemo; Yun V Sun; Yali Li; Alanna Morrison; Christopher Newton-Cheh; Kiang Liu; Santhi K Ganesh; Abdullah Kutlar; Ramachandran S Vasan; Albert Dreisbach; Sharon Wyatt; Joseph Polak; Walter Palmas; Solomon Musani; Herman Taylor; Richard Fabsitz; Raymond R Townsend; Daniel Dries; Joseph Glessner; Charleston W K Chiang; Thomas Mosley; Sharon Kardia; David Curb; Joel N Hirschhorn; Charles Rotimi; Alexander Reiner; Charles Eaton; Jerome I Rotter; Richard S Cooper; Susan Redline; Aravinda Chakravarti; Daniel Levy Journal: Hum Mol Genet Date: 2011-03-21 Impact factor: 6.150
Authors: Ervin R Fox; Solomon K Musani; Aurelian Bidulescu; Harsha S Nagarajarao; Tandaw E Samdarshi; Samson Y Gebreab; Jung Hye Sung; Michael W Steffes; Thomas J Wang; Herman A Taylor; Ramachandran S Vasan Journal: Circulation Date: 2011-08-08 Impact factor: 29.690
Authors: Naveen L Pereira; Pinar Aksoy; Irene Moon; Yi Peng; Margaret M Redfield; John C Burnett; Eric D Wieben; Vivien C Yee; Richard M Weinshilboum Journal: J Mol Cell Cardiol Date: 2010-08-06 Impact factor: 5.000
Authors: Amanda A Fox; Charles D Collard; Stanton K Shernan; Christine E Seidman; Jonathan G Seidman; Kuang-Yu Liu; Jochen D Muehlschlegel; Tjorvi E Perry; Sary F Aranki; Christoph Lange; Daniel S Herman; Thomas Meitinger; Peter Lichtner; Simon C Body Journal: Anesthesiology Date: 2009-04 Impact factor: 7.892
Authors: Valentina Cannone; Angelo Baldassare Cefalu'; Davide Noto; Christopher G Scott; Kent R Bailey; Giovanni Cavera; Michele Pagano; Michelangelo Sapienza; Maurizio R Averna; John C Burnett Journal: Diabetes Care Date: 2013-05-01 Impact factor: 19.112